Latest news with #CropScience
Yahoo
07-06-2025
- Business
- Yahoo
Goldman Sachs Upgrades Bayer (BAYRY) to Buy
On Thursday, Goldman Sachs analyst James Quigley upgraded Bayer Aktiengesellschaft (OTC:BAYRY) to Buy from Neutral, while setting a price target of EUR 33. Quigley indicated that the stock's risk/reward profile appears positive as it approaches H2 2025, with potential catalysts that could drive a re-rating in the medium term. A closeup of pills in a pharmacy, representing the high quality medications of the company. This upgrade follows Bayer's strong operational start to the year, characterized by cost discipline in its Crop Science division and robust momentum in its underlying Pharmaceuticals business. Goldman Sachs suggests that these factors indicate Bayer may have reached the bottom of its negative earnings revision cycle. In key business developments, Bayer's EPS stood at EUR 2.49 in Q1 2025, keeping the company on track to achieve EUR 4.50 to 5.00 at constant currencies for the full year. While sales in the company's Crop Science division declined by 3% due to regulatory impacts affecting higher-margin sales, the Pharmaceuticals segment sales grew by 4% due to an 80% year-over-year increase in Nubeqa and Kerendia sales. Nubeqa is a prostate cancer drug, while Kerendia is used to treat chronic kidney disease associated with type 2 diabetes. The Consumer Health segment sales also increased by 2.5%. Bayer Aktiengesellschaft (OTC:BAYRY) is a global life science company. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. While we acknowledge the potential of BAYRY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Related Content OTC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Zawya
20-05-2025
- Business
- Zawya
Bayer to close historic German factory in 2028 amidst sweeping restructuring
Bayer has announced plans to shut down its herbicide production and development operations at the Frankfurt am Main site by the end of 2028, marking the first closure of a German factory in the company's 161-year history. This decision is part of a broader restructuring of Bayer's Crop Science division, driven by global overcapacity, intense competition from low-cost Asian manufacturers, and increasing regulatory constraints in Europe. The Frankfurt facility, located in Industriepark Höchst, currently employs approximately 500 people. Bayer intends to sell or relocate parts of these operations, though the exact number of job losses has not been disclosed. The company has expressed its commitment to working with employee representatives to find suitable solutions for affected workers. Litigation, losses, layoffs This move is part of a larger effort by Bayer to streamline operations and reduce costs amid financial challenges. In the first quarter of 2025, Bayer reported a significant drop in net income, falling over 35% to €1.3bn from €2bn a year earlier. The decline was attributed to a near-tripling of litigation and restructuring costs to €587m and weakening sales performance. The company is also grappling with numerous US lawsuits alleging its glyphosate-based herbicide Roundup causes cancer, claims Bayer denies and is appealing. Despite these challenges, Bayer's pharmaceuticals division showed resilience, with a 4% increase in sales and 13% earnings growth, driven by strong demand for new drugs like Nubeqa and Kerendia. However, crop science revenues declined 4% during the same period. Chief executive officer Bill Anderson remains cautiously optimistic but noted uncertainty due to tariffs and regulatory pressures. The closure of the Frankfurt site and other restructuring measures are part of Bayer's strategy to focus on strategic and innovative technologies in the agriculture sector, aiming to return to growth from next year. All rights reserved. © 2022. Provided by SyndiGate Media Inc. (
Associated Press
12-05-2025
- Business
- Associated Press
Passage of New Georgia Bill a Win for Farmers
ST. LOUIS--(BUSINESS WIRE)--May 12, 2025-- Farmers and others in agriculture applaud Governor Brian Kemp and the Georgia General Assembly for supporting the crop protection tools so important to Georgia's farmers' ability to produce affordable, safe, abundant food. With Governor Kemp signing SB 144, Georgia has taken the step to re-affirm the authority of the U.S. Environmental Protection Agency's (EPA) scientific rulings on the safety of crop protection products. 'The signing of SB 144 by Governor Kemp demonstrates that Georgia stands with its farmers, who work tirelessly to produce safe and affordable food for communities throughout the state. We thank Governor Kemp and the legislators, farmers and ag groups that supported this important piece of legislation,' said Brian Naber, president, Crop Science North America & Australia/New Zealand Region. 'At Bayer, we are committed to developing agricultural innovations that help farmers thrive. This is important not only for Georgia's farmers and American agriculture, but also the everyday American worried about the cost of groceries, which could increase if these vital tools went away. We hope states around the country considering similar legislation will also support farmers and the tools critical to their success.' This legislation would directly address – and reinforce – the integrity of the regulatory process and ensure that the EPA's thorough and scientifically based conclusion are adhered to and would further reinforce the health and safety warning labels, which are supported by an extensive regulatory process. We hope the courts will apply this legislation appropriately. Ultimately it will be up to the courts to decide on how they interpret the law, but we're optimistic that it will reinforce the legal certainty regarding claims about the warning label. The passage of SB 144 is possible because of the efforts from lawmakers, commodity groups, farmers and Georgians alike who are committed to the success of Georgia's farms, which along with related industries contribute more than $91 billion to the state's economy. Glyphosate-based herbicides have revolutionized farming by effectively and safely managing weeds, which are among the biggest factors impacting farm yields and the ability to use sustainable farming methods. Like all crop protection products, glyphosate has been subject to rigorous testing and oversight and the EPA and all leading regulatory bodies around the world have repeatedly found glyphosate-based products are safe to use as directed. The newly passed legislation ensures that when the EPA makes its scientifically based conclusions about the label required for a product, that stands and is consistently adhered to. To learn more about glyphosate, visit: View source version on CONTACT: Contact for media inquiries: Brian Leake 314.370.3285 Email:[email protected] KEYWORD: UNITED STATES NORTH AMERICA MISSOURI GEORGIA INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH OTHER HEALTH ENVIRONMENTAL ISSUES PUBLIC POLICY/GOVERNMENT OTHER SCIENCE OTHER NATURAL RESOURCES ENVIRONMENT SUSTAINABILITY AGRICULTURE NATURAL RESOURCES SCIENCE STATE/LOCAL OTHER POLICY ISSUES SOURCE: Bayer Copyright Business Wire 2025. PUB: 05/12/2025 09:32 AM/DISC: 05/12/2025 09:31 AM
Reuters
12-05-2025
- Business
- Reuters
Bayer to restructure German agriculture activities amid Asian competition
FRANKFURT, May 12 (Reuters) - Bayer ( opens new tab said on Monday it would focus production, research and development of its Crop Science division in Germany on "strategic technologies" to react to competitive pressure. "Manufacturers of generic crop protection products, particularly from Asia, have built significant overcapacity over recent years and are pushing onto the market with persistently low prices, some of which are below the manufacturing costs of crop protection products in Europe," the company said in a statement.
Yahoo
04-03-2025
- Business
- Yahoo
Bayer faces investors' impatience ahead of fourth-quarter results
By Patricia Weiss FRANKFURT (Reuters) -Bayer's CEO is facing increasing investor pressure to deliver on turnaround efforts and reverse a forecast earnings decline this year, as the group prepares to release quarterly results on Wednesday. CEO Bill Anderson is in the middle of cutting managerial jobs, speeding up decision-making and slashing red tape, and has put on hold plans to break up Bayer diversified businesses. But investors are questioning whether he is doing enough amid a plethora of problems that have dragged shares lower. Taking the helm in mid-2023, Anderson inherited costly U.S. litigation over disputed claims that Bayer's weedkiller glyphosate causes cancer. Later that year, a once-promising blood thinner flopped in a trial, leaving a massive gap in Bayer's drug development lineup. Late last year, the drugs and pesticides maker said weakness in global agriculture markets, the lifeblood of Bayer's Crop Science unit, meant the earnings decline was likely to extend into 2025. "We want to see successes that will actually support the share price," said Ingo Speich, head of sustainability and corporate governance at mutual funds firm Deka, a Bayer shareholder. "By the end of the year, Anderson will have been chief executive for almost three years. If a CEO cannot make an impact over such a period of time, he will not be the right one for the job," he added. Markus Manns, a portfolio manager at mutual funds firm Union Investment, another Bayer shareholder, said Anderson had made steps in the right direction, but the stock market was waiting for more. The upcoming fourth-quarter results "will arguably be one of the last few opportunities for Bill Anderson to change course", said Manns. Recent market trends may provide some respite, with U.S. agrichemicals firm Corteva last month posting a smaller fourth-quarter loss helped by strong sales volumes, and Germany's BASF, also competing with Bayer in farming products, flagging volume gains during the fourth quarter. But more specific to Bayer, investors will look for clues on how severely a delay in U.S. approval of a new generation of soy seeds to go with weedkiller Dicamba will dent earnings. Analysts on average expect 2025 adjusted operating income to slip to 9.44 billion euros ($9.96 billion), down from an estimated 10.0 billion in 2024. For the fourth quarter of last year, they expect a 25% decline to 2.27 billion. Bayer's $63 billion purchase of U.S. seeds and pesticides producer Monsanto under Anderson's predecessor in 2018 was a long-term bet on robust growth in farming supplies that has misfired. The deal has left a persistent debt burden, projected by Bayer to decline slightly to up to 33.5 billion euros at the end of 2024. The CEO has vowed the company would do more to contain litigation uncertainty and boost operational performance, on its way to a "bright future". He has pointed to strong launches of the pharmaceutical unit's new drugs, Nubeqa for prostate cancer and Kerendia for kidney disease. Bestselling blood-thinner Xarelto, however, is in decline as it loses patent protection. ($1 = 0.9481 euros) (Additional reporting and writing by Ludwig Burger; Editing by Jan Harvey)
